FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031171659> ?p ?o ?g. }

• W2031171659 endingPage "1232" @default.
• W2031171659 startingPage "1222" @default.
• W2031171659 abstract "Abstract The epithelial-to-mesenchymal transition (EMT) in prostate cancer (PCA) cells is considered prerequisite for acquiring migratory/invasive phenotype, and subsequent metastasis. We hypothesized that promoting the E-cadherin expression in PCA cells by using nontoxic phytochemicals, like silibinin, would prevent EMT and consequently invasiveness. Our results showed that silibinin treatment (5–90 μmol/L) significantly inhibits migratory and invasive potential of advance human PCA PC3, PC3MM2, and C4–2B cells in in vitro assays. Importantly, the antimigratory/antiinvasive efficacy of silibinin was not due to its cytotoxicity toward PCA cells. Molecular analyses showed that silibinin increases E-cadherin level that was localized mainly at cellular membrane as evidenced by subcellular fractional and confocal analyses in PC3 cells, which might be responsible for morphologically observed shift toward epithelial character. Silibinin also decreased the levels of Slug, Snail, phospho-Akt(ser473), nuclear β-catenin, phospho-Src(tyr419) and Hakai; together they play an important role in regulating E-cadherin expression/function and EMT. Similar silibinin effects on E-cadherin, β-catenin, phospho-Src(tyr419), and Hakai levels were also observed in PC3MM2 and C4–2B PCA cells. Selective Src inhibition by dasatinib also showed increased E-cadherin expression in PC3 cells suggesting a possible involvement of Src inhibition in silibinin-caused increase in E-cadherin level. Additional studies in PC3 cells with stable knock-down of E-cadherin expression revealed that antimigratory/antiinvasive efficacy of silibinin is in-part dependent on E-cadherin expression. Together, our results showing antimigratory/antiinvasive effects of silibinin and associated mechanisms suggest that silibinin should be tested further in clinically relevant animal models toward exploiting its potential benefits against metastatic PCA. Cancer Prev Res; 4(8); 1222–32. ©2011 AACR." @default.
• W2031171659 created "2016-06-24" @default.
• W2031171659 creator A5027734680 @default.
• W2031171659 creator A5048444823 @default.
• W2031171659 creator A5059572873 @default.
• W2031171659 creator A5062069796 @default.
• W2031171659 date "2011-08-01" @default.
• W2031171659 modified "2023-10-11" @default.
• W2031171659 title "Role of E-cadherin in Antimigratory and Antiinvasive Efficacy of Silibinin in Prostate Cancer Cells" @default.
• W2031171659 cites W1735268000 @default.
• W2031171659 cites W1965025928 @default.
• W2031171659 cites W1965762667 @default.
• W2031171659 cites W1968548847 @default.
• W2031171659 cites W1974978671 @default.
• W2031171659 cites W1983528955 @default.
• W2031171659 cites W1989901669 @default.
• W2031171659 cites W1992642006 @default.
• W2031171659 cites W1998203126 @default.
• W2031171659 cites W2002160125 @default.
• W2031171659 cites W2002801265 @default.
• W2031171659 cites W2006444511 @default.
• W2031171659 cites W2008273587 @default.
• W2031171659 cites W2016424446 @default.
• W2031171659 cites W2034269086 @default.
• W2031171659 cites W2039299190 @default.
• W2031171659 cites W2045269572 @default.
• W2031171659 cites W2047392037 @default.
• W2031171659 cites W2074510695 @default.
• W2031171659 cites W2079079774 @default.
• W2031171659 cites W2081596675 @default.
• W2031171659 cites W2082055110 @default.
• W2031171659 cites W2085033745 @default.
• W2031171659 cites W2088244733 @default.
• W2031171659 cites W2097707819 @default.
• W2031171659 cites W2099711571 @default.
• W2031171659 cites W2105772211 @default.
• W2031171659 cites W2109008667 @default.
• W2031171659 cites W2111631361 @default.
• W2031171659 cites W2113489470 @default.
• W2031171659 cites W2119084145 @default.
• W2031171659 cites W2123640548 @default.
• W2031171659 cites W2124281312 @default.
• W2031171659 cites W2126709248 @default.
• W2031171659 cites W2127851117 @default.
• W2031171659 cites W2130979736 @default.
• W2031171659 cites W2135306934 @default.
• W2031171659 cites W2135863036 @default.
• W2031171659 cites W2146282577 @default.
• W2031171659 cites W2150823776 @default.
• W2031171659 cites W2158734599 @default.
• W2031171659 cites W2161146123 @default.
• W2031171659 cites W2167030358 @default.
• W2031171659 doi "https://doi.org/10.1158/1940-6207.capr-10-0370" @default.
• W2031171659 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3151351" @default.
• W2031171659 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21546539" @default.
• W2031171659 hasPublicationYear "2011" @default.
• W2031171659 type Work @default.
• W2031171659 sameAs 2031171659 @default.
• W2031171659 citedByCount "68" @default.
• W2031171659 countsByYear W20311716592012 @default.
• W2031171659 countsByYear W20311716592013 @default.
• W2031171659 countsByYear W20311716592014 @default.
• W2031171659 countsByYear W20311716592015 @default.
• W2031171659 countsByYear W20311716592016 @default.
• W2031171659 countsByYear W20311716592017 @default.
• W2031171659 countsByYear W20311716592018 @default.
• W2031171659 countsByYear W20311716592019 @default.
• W2031171659 countsByYear W20311716592020 @default.
• W2031171659 countsByYear W20311716592021 @default.
• W2031171659 countsByYear W20311716592022 @default.
• W2031171659 countsByYear W20311716592023 @default.
• W2031171659 crossrefType "journal-article" @default.
• W2031171659 hasAuthorship W2031171659A5027734680 @default.
• W2031171659 hasAuthorship W2031171659A5048444823 @default.
• W2031171659 hasAuthorship W2031171659A5059572873 @default.
• W2031171659 hasAuthorship W2031171659A5062069796 @default.
• W2031171659 hasBestOaLocation W20311716591 @default.
• W2031171659 hasConcept C108636557 @default.
• W2031171659 hasConcept C121608353 @default.
• W2031171659 hasConcept C126322002 @default.
• W2031171659 hasConcept C1491633281 @default.
• W2031171659 hasConcept C149402561 @default.
• W2031171659 hasConcept C185592680 @default.
• W2031171659 hasConcept C2777130413 @default.
• W2031171659 hasConcept C2779013556 @default.
• W2031171659 hasConcept C2780192828 @default.
• W2031171659 hasConcept C502942594 @default.
• W2031171659 hasConcept C55493867 @default.
• W2031171659 hasConcept C62478195 @default.
• W2031171659 hasConcept C71924100 @default.
• W2031171659 hasConcept C76419328 @default.
• W2031171659 hasConcept C86803240 @default.
• W2031171659 hasConcept C95444343 @default.
• W2031171659 hasConcept C96232424 @default.
• W2031171659 hasConceptScore W2031171659C108636557 @default.
• W2031171659 hasConceptScore W2031171659C121608353 @default.
• W2031171659 hasConceptScore W2031171659C126322002 @default.
• W2031171659 hasConceptScore W2031171659C1491633281 @default.

• next